Effect of Protein Supplementation on Craving in Subjects Hospitalised for Addiction Treatment
NCT ID: NCT06459609
Last Updated: 2024-10-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
30 participants
INTERVENTIONAL
2024-10-01
2025-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will be conducted according a crossover design with a one-week phase with protein supplementation (P) and a one-week phase without protein supplementation (SP).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Utilizing Protein During Weight Loss to Impact Physical Function
NCT03074643
Protein Supplementation and Muscle Function in the Elderly
NCT03815201
The Effects of Protein Source on Appetite Control, Satiety, and Subsequent Food Intake: A Clinical Screening Study
NCT03595436
Dietary Protein Requirement of Elderly Men and Women
NCT00812500
Brief Title: The Role of Nutrition in the Rehabilitation of Patients With Eating Disorders After a Vascular Stroke.
NCT06961825
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Protein supplementation takes the form of a powder sachet mixed with yoghurt or compote. It will be given twice a day, at the same time (8am and 4pm).
Patients will be enrolled at the admission to the addiction unit. They will be assessed psychologically, addictologically and nutritionally for one week and then will be randomised. Patients will be asked to assess their cravings, dietary needs, consumption of addictive substances and palatable foods.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
P - SP
1 week with protein supplementation (P) then one week without protein supplementation (SP)
protein supplementation
Protein supplementation takes the form of a powder sachet mixed with yoghurt or compote. It will be given twice a day, at the same time.
SP - P
1 week without protein supplementation (SP) then one week with protein supplementation (P)
protein supplementation
Protein supplementation takes the form of a powder sachet mixed with yoghurt or compote. It will be given twice a day, at the same time.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
protein supplementation
Protein supplementation takes the form of a powder sachet mixed with yoghurt or compote. It will be given twice a day, at the same time.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 18 and over
* Admitted for complex care in the addictology department
* Person affiliated to or benefiting from a social security scheme
* Free, informed and written consent signed by the participant and the investigator
Exclusion Criteria
* Admitted to hospital for less than 3 weeks
* Severe somatic or psychiatric pathology incompatible with understanding assessment tools
* Difficulty understanding and/or writing French
* Presumed non-compliant in completing the patient diary
* Person participating in another research study with an exclusion period still in progress
* Person under legal protection (guardianship, curatorship)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier de PAU
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CH de Pau
Pau, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-A01230-47
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.